Viewing nowCombinationTragliflozin Duo Tablet 2.5/850mg
Linagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.

MFDS item code 201902170 · Approved 2019.04.09 · Insurance code 653806290
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication helps improve blood sugar control in patients with type 2 diabetes by combining linagliptin and metformin. It acts as an adjunct to diet and exercise therapy to effectively manage blood glucose levels. This contributes to the prevention of complications and the maintenance of a healthy life.
The dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This drug is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior history of pharmacologic treatment for diabetes whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this drug 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this drug 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this drug should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this drug should start at their existing doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this drug should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 3. Patients Requiring Cautious Administration). 5. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this drug should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 3. Patients Requiring Cautious Administration). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic drug to this drug. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use 2. Patients in Whom This Drug Must Not Be Administered).
This medication helps control blood sugar levels. However, during this treatment, there is a risk of serious side effects such as lactic acidosis. Lactic acidosis is a condition caused by excessive accumulation of lactate in the body, which can be life-threatening if not treated immediately. This medication should not be administered to patients with certain conditions. For example, individuals allergic to the components of this drug, those with type 1 diabetes, patients with severe renal impairment, acute heart diseases, liver dysfunction, pregnant or breastfeeding women should not take this medication. When using it in conjunction with other hypoglycemic agents that pose a risk of hypoglycemia, particular caution should be taken for symptoms of low blood sugar, and the dosages of other medications may need to be adjusted as necessary. Patients with decreased renal function should undergo regular kidney function tests, and the medication should not be taken if kidney function is severely compromised. Patients with unstable heart function or those with acute heart diseases should use this medication cautiously. In cases where iodinated contrast media is administered during radiological examinations, the use of this medication should be paused before and after the contrast agent administration until renal function stabilizes. For patients undergoing surgery, the medication should be discontinued 48 hours prior to the procedure and can be resumed after confirming normal recovery of kidney function. During the treatment with this medication, acute pancreatitis or skin blistering diseases may occur, so if symptoms such as abdominal pain or skin abnormalities appear, immediate consultation with a doctor is necessary. This medication may lower vitamin B12 levels, so regular checks for vitamin B12 deficiency are needed for long-term use. Pregnant women or those planning to conceive should avoid using this medication, and breastfeeding women are also advised against it. Safety in children and adolescents has not been established, so it should not be used in children under 10 years of age. Elderly patients commonly have decreased renal function; therefore, treatment should be conducted at the minimum dose while regularly monitoring renal function during usage. There is insufficient research on the effects of this medication on driving and operating machinery, so caution is required during use. In case of overdose, treatments such as removing the drug from the gastrointestinal tract or dialysis may be necessary. This medication should be stored in a tightly closed container, avoiding moisture and direct sunlight, and should not be transferred to another container.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. Recommended storage temperature is between 1 and 30 degrees Celsius, to maintain the effectiveness of the drug for a longer period.
Bright orange, bilaterally convex oval film-coated tablet
10 tablets/bottle, 30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle, 30 tablets/box (10 tablets/PTP x 3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.